Pelareorep-based combination therapy improves glioblastoma patient survival
In a Phase Ib trial, pelareorep with GM-CSF, chemoradiotherapy and…
In a Phase Ib trial, pelareorep with GM-CSF, chemoradiotherapy and temozolomide increased progression-free survival by an average of eight months.